Ramipril Shortage UK 2026 — Live Status & Alternatives

Is there a ramipril shortage in the UK? Not confirmed either way. The last official notice for ramipril (DHSC MSN/2026/022) gave a resupply date that has passed, and DHSC has not confirmed supply is back. Check with your pharmacy. Official data last checked 12 November 2026, 06:18 UTC.

SSP087 for ramipril 1.25mg capsules ended on 30 October 2026 (NHSBSA), and DHSC's end-of-October estimate for 1.25mg, 2.5mg, 5mg and 10mg capsules (MSN/2026/043) has passed with no update: supply is not confirmed back. Here's what patients need to know about supply, switching, and clinical alternatives.

Quick Answer: Is Ramipril in Shortage?

Not confirmed over. DHSC MSN/2026/043 said ramipril 1.25mg, 2.5mg, 5mg and 10mg capsules were in limited supply until the end of October 2026. That date has passed, and DHSC has not issued an update or said supply is back (checked 1 November 2026). The Department of Health and Social Care (DHSC) issued Serious Shortage Protocol SSP087 for ramipril 1.25mg capsules on 22 April 2026. It let community pharmacies limit dispensing to a maximum of one month's supply per prescription — even if your prescription was normally for two or three months — with no prescription charge on NHS prescriptions supplied under it. NHSBSA lists it as running to 30 October 2026 (amended 23 July 2026), and it has ended without an extension: since then, prescriptions for ramipril 1.25mg capsules must be dispensed in accordance with the prescription (Community Pharmacy England, relaying DHSC). Do not stop taking ramipril: if your pharmacy cannot fill your prescription, ask your pharmacist or GP.

Ramipril 1.25mg, 2.5mg, 5mg and 10mg tablets remain available but cannot support uplift in demand (DHSC MSN/2026/043). The April notice (MSN/2026/022) said ramipril oral solution remains available but cannot support increased demand. DHSC MSN/2026/043 also says: “Alternative ACE inhibitors and ARBs remain available; however, routine switching is not recommended as usage is significantly lower than that of ramipril, so could risk compromising other supply chains.”

Separately, a Class 2 recall was issued on 20 April 2026 for one batch of Ramipril 10mg capsules (manufactured by Crescent Pharma) due to a packaging error — some cartons contained 5mg blister strips instead of 10mg. This is a safety issue, not a supply issue, but it adds pressure to the overall Ramipril supply chain.

What Is Ramipril?

The Drug in Plain English

Ramipril is an ACE inhibitor — one of the most commonly prescribed blood pressure medications in the UK. Over 35 million Ramipril items were dispensed in England alone during 2025, making it one of the top ten prescribed drugs in the country. It belongs to a family of medicines that all work in a similar way, but Ramipril is particularly favoured because it has a long half-life (stays in your body for a while) and can be taken once daily.

Like all ACE inhibitors, Ramipril is a prodrug — meaning the tablet or capsule you swallow is not the active medicine itself. Your liver converts it into ramiprilat, the molecule that actually does the work. This conversion is why the drug takes a little time to reach full effect (typically 2–4 weeks), and why you shouldn't expect your blood pressure to drop immediately after the first dose.

How Ramipril Works in Your Body

Your body has a built-in system called the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure, fluid balance, and kidney function. Here's the simplified version:

1. Step 1: Your kidneys release a hormone called renin when blood pressure drops or sodium levels fall.
2. Step 2: Renin converts angiotensinogen (a protein in your blood) into angiotensin I.
3. Step 3: An enzyme called ACE (angiotensin-converting enzyme) converts angiotensin I into angiotensin II.
4. Step 4: Angiotensin II is a powerful vasoconstrictor — it narrows your blood vessels and tells your adrenal glands to release aldosterone, which makes your kidneys hold onto salt and water.
5. Step 5: Narrowed vessels + extra fluid = higher blood pressure.

Ramipril blocks Step 3. By inhibiting ACE, it stops the production of angiotensin II. Without angiotensin II, your blood vessels relax and widen (vasodilation), and your kidneys release less aldosterone, so you lose a little more salt and water in urine. The combined effect lowers your blood pressure and reduces the workload on your heart.

ACE also breaks down a substance called bradykinin, which promotes vasodilation. By blocking ACE, Ramipril increases bradykinin levels — this gives an extra blood-pressure-lowering boost. Unfortunately, this is also why some people get a dry, tickly cough on ACE inhibitors — bradykinin irritates the airways.

What Ramipril Is Used For

The NHS and BNF/NICE guidelines list Ramipril for:

• High blood pressure (hypertension) — first-line treatment for adults under 55 who are not of African or Caribbean family origin (NICE NG136)
• Heart failure — reduces strain on the heart and improves long-term survival (NICE NG106)
• After a heart attack — started 3–10 days post-MI to prevent further cardiac damage
• Diabetic kidney disease — protects the kidneys from protein leakage and slows decline (NICE NG28)
• Prevention of cardiovascular events — in high-risk patients (e.g., HOPE trial showed 20% reduction in MI, stroke and CV death)

Ramipril Dosages and Forms Used in the UK

National supply signal only: This table reflects published UK shortage and recall notices, not stock at any individual pharmacy. “No national shortage alert recorded” does not mean a pharmacy has stock. Local stock may still be unavailable, so call before travelling.

How Is Ramipril Made? — From Molecules to Medicine

You asked how medicines are crafted and what they're made of. Ramipril is a perfect example of the extraordinary chemistry that goes into a single pill. The active ingredient is not a simple molecule — it contains five chiral centres, meaning there are 32 possible stereoisomers, and only one specific 3D arrangement — the (2S,3aS,6aS)-isomer — has the pharmacological effect. Getting that exact shape is what makes the synthesis complex and expensive.

The Two Building Blocks

Ramipril is assembled from two complex chiral intermediates, like putting together two bespoke Lego pieces:

The Manufacturing Process — Step by Step

Step 1: Synthesising the Alanine Derivative (Building Block A)

The first major intermediate starts from L-alanine (one of the 20 natural amino acids) and ethyl 4-phenyl-4-oxobut-2-enoate (a benzene-ring-containing compound). These undergo a stereoselective reductive amination — essentially a controlled chemical marriage where hydrogen is added in a specific direction, guided by a catalyst, so only the desired (S)-stereochemistry forms. One patent describes using catecholborane as the reducing agent with a chiral catalyst to achieve >95% selectivity for the correct isomer.

Alternative routes use hydrogenation of precursor compounds over specialised catalysts, sometimes with thiourea or urea additives to improve yield and purity. This step is critical — if the wrong stereoisomer forms here, the final Ramipril won't work properly in your body.

Step 2: Creating the Bicyclic Core (Building Block B)

The (S,S,S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid core is a fused two-ring nitrogen-containing structure. In older manufacturing methods, chemists created a racemic mixture (equal parts of left- and right-handed molecules) and then had to painstakingly separate them using chiral resolution — typically with L-(+)-mandelic acid or enantioselective enzymatic hydrolysis. This is wasteful because half the material is discarded.

Modern synthesis routes aim for enantioselective construction from the start, using chiral catalysts or enzymes to build only the desired (S,S,S) form. The bicyclic core is often protected as its benzyl ester hydrochloride salt during this process — the benzyl group acts as a chemical "mask" that prevents unwanted reactions until the right moment.

Step 3: Coupling the Two Blocks

This is the big moment. The alanine derivative (Building Block A) and the bicyclic core (Building Block B) are brought together in a condensation reaction to form an amide bond — the same type of bond that links amino acids in proteins. The coupling agents DCC and HOBt activate the carboxylic acid group on the bicyclic core, making it reactive enough to bond with the nitrogen on the alanine side chain.

The reaction is carried out in an organic solvent such as dichloromethane, toluene, or isopropanol, under carefully controlled temperature and pH conditions. Organic bases like triethylamine are added to neutralise acidic byproducts.

Step 4: Deprotection and Purification

After coupling, the benzyl protecting group must be removed — this is called debenzylation. It's done by catalytic hydrogenation using palladium on charcoal (Pd/C) under hydrogen gas pressure. The palladium catalyst selectively cleaves the benzyl group without damaging the rest of the molecule.

The crude Ramipril then undergoes rigorous purification: crystallisation, washing, and chromatography to isolate the pharmacologically active (2S,3aS,6aS)-isomer and remove any impurities. Pharmaceutical-grade Ramipril must meet strict purity standards — typically >99.5% — before it can be used in tablets or capsules.

From API to Pill — The Excipients

The active pharmaceutical ingredient (API) is only a tiny fraction of what you swallow. A 2.5mg Ramipril tablet contains just 2.5 milligrams of actual drug — the rest is made up of excipients (inactive ingredients) that help the tablet form, dissolve, and stay stable:

• Calcium sulphate dihydrate — filler and binder, gives the tablet bulk
• Pregelatinized starch — acts as a disintegrant, helping the tablet break up in your stomach
• Sodium bicarbonate — pH buffer, helps Ramipril stay chemically stable
• Microcrystalline cellulose — compressible filler, makes the tablet hard enough to handle
• Magnesium stearate — lubricant, stops the tablet sticking to manufacturing equipment
• Hypromellose — coating agent, controls release and makes the tablet easier to swallow
• Titanium dioxide + iron oxides — pigments for capsule shells, so different strengths have different colours

The capsule shell itself is typically gelatin — derived from collagen — with colourants to distinguish strengths. Ramipril 1.25mg capsules are often pink or red; 2.5mg may be yellow or orange; 5mg and 10mg have their own colour codes depending on the manufacturer.

The Current Shortage — What Is Actually Happening

Timeline of Events

Why Is Ramipril in Shortage?

The exact cause of the 1.25mg capsule shortage has not been fully disclosed by the DHSC, but several factors are known to contribute to ACE inhibitor supply disruptions in general:

• Manufacturing bottlenecks — The complex stereoselective synthesis means production cannot be ramped up quickly. Only a handful of manufacturers globally produce pharmaceutical-grade Ramipril API.
• Raw material scarcity — Starting materials like L-alanine derivatives and specialised chiral catalysts come from a concentrated supply base, often in India and China. Any disruption (pandemic, geopolitical conflict, environmental regulation) ripples through.
• Surge demand from recall — The Class 2 recall on 10mg capsules created a sudden spike in demand for other strengths as patients were switched and pharmacies re-stocked.
• Formulation-specific issues — Capsule manufacturing involves different equipment, gelatin shell suppliers, and fill-weight precision compared to tablets. If a capsule-filling line goes down or a gelatin supplier has issues, capsule supply drops before tablet supply.
• Low-margin generic economics — Ramipril is off-patent and cheap. Manufacturers have little financial incentive to maintain excess capacity, so there's no buffer when demand spikes.

Which Patients Are Affected?

Not every Ramipril patient is impacted equally:

• Most affected: Patients on ramipril capsules — 1.25mg, 2.5mg, 5mg and 10mg capsules are named in DHSC MSN/2026/043, whose end-of-October 2026 estimate has passed with no update, and SSP087 (ended 30 October 2026) covered 1.25mg capsules. This is often the starting dose for elderly patients, those with kidney impairment, or post-heart-attack patients.
• Moderately affected: Patients on 10mg capsules from the recalled Crescent Pharma batch (EL26A19). If you have 10mg capsules, check the batch number on your pack.
• Less affected: Patients on tablets (all strengths) or oral solution. These remain available but cannot support increased demand (DHSC MSN/2026/043 for tablets; MSN/2026/022 for the oral solution).
• Switching: DHSC MSN/2026/043 says: “Alternative ACE inhibitors and ARBs remain available; however, routine switching is not recommended as usage is significantly lower than that of ramipril, so could risk compromising other supply chains.”

What to Do If You Take Ramipril

Step-by-Step Action Plan

1. Check your current supply. Count how many days of Ramipril you have left. If it's less than 14 days, act now. If it's more than 28 days, you have time but should still check with your pharmacy at your next refill.
2. Check your pack. Is it capsules or tablets? What strength? If you have 1.25mg capsules, you're in the shortage group. If you have 10mg capsules, check the batch number against the recall notice.
3. Call your pharmacy. Ask whether they can supply your prescribed capsules. SSP087 ended on 30 October 2026, so they can no longer use it to limit ramipril 1.25mg capsules to one month's supply; if stock is short, ask when they expect more. A change from capsules to tablets needs your prescriber; DHSC says ramipril tablets “remain available but cannot support uplift in demand” (MSN/2026/043).
4. About the oral solution: DHSC MSN/2026/022 said ramipril oral solution remains available but cannot support increased demand. A change of form needs your prescriber.
5. If no Ramipril form is available, contact your GP. DHSC MSN/2026/043 says: “Alternative ACE inhibitors and ARBs remain available; however, routine switching is not recommended as usage is significantly lower than that of ramipril, so could risk compromising other supply chains.” Explain the shortage and ask about switching to an alternative ACE inhibitor (lisinopril, perindopril, enalapril) or an ARB (losartan, candesartan). Your GP will know your full medical history and can choose the safest option.
6. If your GP switches you, your blood pressure should be checked within 1–2 weeks of starting the new medicine. ACE inhibitors can affect kidney function and potassium levels, so a blood test may be needed.

Specific Questions to Ask Your Pharmacist

• "SSP087 has ended — can you supply my full prescription?" (Since 30 October 2026, prescriptions for ramipril 1.25mg capsules must be dispensed as written.)
• "Do you have any 1.25mg tablets in stock, or can you order them?"
• "Can you check other branches in your chain for stock?"
• "If I need to switch medicines, do you need a new prescription from my GP?"
• "Do you have the oral solution as an emergency backup?"

Specific Questions to Ask Your GP

• "Given the Ramipril shortage, should I switch to lisinopril or perindopril?"
• "What dose of the alternative would be equivalent to my current Ramipril dose?"
• "Do I need a blood test before switching, or 1–2 weeks after?"
• "Are there any reasons I shouldn't take an ACE inhibitor alternative?" (e.g. if you had angioedema on Ramipril, you may need an ARB instead)
• "If I can't get any ACE inhibitor, what's the next option?" (calcium channel blockers like amlodipine, or thiazide-like diuretics like indapamide)

Alternatives to Ramipril — Clinical Guide

The good news is that Ramipril is not unique. There are several medicines in the same class (ACE inhibitors) and a related class (ARBs) that work in a very similar way. Your GP will choose the best alternative based on your specific condition, other medications, kidney function, and any side effects you've had.

See also: our dedicated Ramipril related-medicines page — a single-page summary of every alternative below, with BNF/NICE citations and indication-by-indication guidance.

Alternative 1: Lisinopril (Most Common Switch)

Alternative 2: Perindopril Arginine / Erbumine

Alternative 3: Enalapril

Alternative 4: Losartan (ARB — If You Can't Tolerate ACE Inhibitors)

Alternative 5: Candesartan (ARB)

Quick Reference: ACE Inhibitor Dose Equivalents

How Long Will the Ramipril Shortage Last?

DHSC MSN/2026/043 said ramipril 1.25mg, 2.5mg, 5mg and 10mg capsules were in limited supply until the end of October 2026. That date has passed, and DHSC has not issued an update, given a new date or said supply is back (checked 1 November 2026). SSP087 ran from 22 April 2026 to 30 October 2026 (NHSBSA; amended 23 July 2026) and has ended without an extension. Supply disruptions often extend beyond initial estimates, especially when the root cause is manufacturing capacity rather than a temporary logistics issue.

Several factors could extend the shortage:

• Manufacturing recovery time: If the shortage is due to a production line issue or raw material scarcity, it can take 2–3 months to restore full capacity once the problem is fixed.
• Demand surge: Every patient switched from capsules to tablets increases demand for tablets. If tablet demand exceeds tablet manufacturing capacity, a secondary shortage could occur.
• Geopolitical factors: The ongoing conflict involving Iran and potential blockades in the Strait of Hormuz could disrupt shipping routes for pharmaceutical raw materials from Asia.
• Further recalls: If additional batches are found to have quality issues, further recalls could tighten supply.

MediWatch will update this page immediately when the DHSC issues a new notification or a new Serious Shortage Protocol, or confirms that normal supply has resumed. See our back-in-stock tracker for other shortages. Sign up for alerts below to be notified the moment the shortage ends.

Ramipril Shortage History

Ramipril has faced supply disruptions before — this is not an isolated incident:

• August 2024: SSP071 was issued for Ramipril 2.5mg tablets. Pharmacies could substitute tablets with capsules. The protocol ran from 6 August 2024 to 29 November 2024 (NHSBSA).
• 2023: No major Ramipril shortages recorded in DHSC notifications.
• April to October 2026: SSP087 for 1.25mg capsules ran from 22 April to 30 October 2026 and has ended. Plus Class 2 recall on 10mg capsules (April 2026), and DHSC MSN/2026/043 (September 2026) naming all four capsule strengths, whose end-of-October estimate has passed with no update.

The pattern suggests that low-strength Ramipril (1.25mg and 2.5mg) is more vulnerable to shortage than higher strengths. This makes clinical sense — 1.25mg and 2.5mg are the starting doses for elderly patients, post-MI patients, and those with kidney impairment. These patient groups cannot safely start on higher doses, so when low-strength supply fails, there is no clinical workaround within the same drug.

What Is a Serious Shortage Protocol (SSP)?

A Serious Shortage Protocol (SSP) is an emergency measure that the DHSC can activate when a medicine is in critical shortage. It temporarily changes the normal rules around dispensing so that patients can still get treatment.

Under a normal prescription, a pharmacist must supply exactly what the GP wrote — same medicine, same strength, same form. Under an SSP, they have limited flexibility:

• Substitute an alternative strength or form (if the SSP specifically allows it)
• Limit the quantity supplied (e.g. only 1 month instead of 3 months)
• Substitute a different but therapeutically equivalent medicine (if the SSP specifically allows it)

For Ramipril, SSP087 (22 April to 30 October 2026, now ended) allowed pharmacists to limit 1.25mg capsule supply to one month and to supply without a prescription charge on NHS prescriptions when the SSP was used. It did NOT allow pharmacists to supply a different strength, form or medicine (like lisinopril) without a new prescription — you still need your GP for that.

SSPs are time-limited and are reviewed regularly. SSP087's original expiry was 29 May 2026; NHSBSA later listed it as running to 30 October 2026 (amended 23 July 2026), and it ended on that date without a further extension (checked 1 November 2026).

Frequently Asked Questions

Related Shortages & Guides